Volpara Software Supports BreastScreen Australia’s New Breast Density Reporting to Enhance Personalised Cancer Screening

Volpara Software Assesses Breast Density for Over 1 Million Australian Women Annually

WELLINGTON, New Zealand, June 2, 2025 /PRNewswire/ – Volpara Health, a Lunit company and a global leader in software for early breast cancer detection, welcomes BreastScreen Australia's updated guidance on breast density reporting. The new recommendation calls for all BreastScreen services across Australia to provide breast density information to clients, increasing awareness of this crucial risk factor.

Advancing Accurate and Personalised Breast Cancer Screening

Volpara's Scorecard software measures breast density for more than one million Australian women each year, including those screened through BreastScreen Victoria and BreastScreen South Australia. This AI-driven tool helps healthcare professionals deliver consistent and objective density assessments, improving breast cancer risk evaluation for individual patients.

The software uses Volpara® TruDensity™ AI algorithms to provide precise volumetric breast density measurements. Its reliability is backed by clearances from regulatory bodies such as the Therapeutic Goods Administration (TGA), FDA, Health Canada, and CE marking in Europe. Over 400 scientific publications validate its accuracy.

Craig Hadfield, CEO of Volpara Health, stated, “We have worked with clinicians and researchers worldwide for over a decade to make breast composition data and its link to cancer risk more accessible. BreastScreen Australia’s new guidelines reinforce the importance of applying AI in breast density assessment. We encourage women to ask their healthcare providers about how their breast density is evaluated.”

Breast Density: An Important Risk Factor for Detection and Assessment

Breast density affects both the risk of developing breast cancer and the ability to detect it via mammography. In Australia, about 40% of women have dense breasts, with 12% classified as extremely dense. Dense tissue appears white on mammograms, just like tumors, which can hide cancers and delay diagnosis.

Research published in Radiology shows mammography may miss up to 50% of cancers in women with the densest breast tissue. Early detection improves significantly when additional imaging, such as ultrasound or MRI, supplements mammography for these women.

Embracing Personalised Screening for Better Outcomes

Breast density data is integrated into risk models that help identify women at higher risk who may benefit from additional screening. Volpara Scorecard is the only commercial automated software validated for use with both the Tyrer-Cuzick 8 and CanRisk (BOADICEA) models, ensuring consistent breast density measurement.

With BreastScreen Australia's new guidance, Volpara is positioned to support personalised screening strategies and improved risk assessments across the country. Medicare has also introduced reimbursement for high-risk breast MRI screening based on these risk models, reflecting growing recognition of personalised approaches in breast cancer care.

About Volpara Health

Volpara Health develops AI-powered software that assists healthcare providers in evaluating cancer risk, guiding personalised care, and recommending further imaging or interventions. Its solutions are used in over 3,500 facilities worldwide by more than 9,500 technologists, impacting nearly 18 million patients annually.

The software enables radiologists to accurately quantify dense breast tissue and helps technologists optimize mammogram quality. It also streamlines operational processes for compliance and accreditation. Volpara, headquartered in Wellington, New Zealand, with an office in Seattle, is a trusted partner for leading healthcare institutions globally.

For more information, visit www.volparahealth.com.